Applied Molecular Transport Inc (NASDAQ:AMTI) announced topline Phase 2 results from the LOMBARD monotherapy trial for AMT-101 in biologic-naïve and experienced…
Applied Molecular (NASDAQ:AMTI) reported quarterly losses of $(0.65) per share. This is a 4.41 percent increase over losses of $(0.68) per share from the same period last year.